BioMarin Pharma (BMRN) Misses Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.99 +0.53%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.04), $0.02 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $505.3 million versus the consensus estimate of $516.56 million.
GUIDANCE:
BioMarin Pharma sees 2022 revenue of $2.06-2.16 billion, versus the consensus of $2.12 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
